期刊
MOLECULAR CANCER RESEARCH
卷 11, 期 9, 页码 1072-1077出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-13-0040-T
关键词
-
资金
- American Cancer Society [MGO-114877]
- National Science Foundation Graduate Research Fellowship [1000087636]
- Human Frontier Science Program
- Ellison Medical Foundation New Scholar Award
- NIA [R01AG032375]
- Glenn Foundation for Medical Research
Activating point mutations in K-RAS are extremely common in cancers of the lung, colon, and pancreas and are highly predictive of poor therapeutic response. One potential strategy for overcoming the deleterious effects of mutant K-RAS is to alter its posttranslational modification. Although therapies targeting farnesylation have been explored, and have ultimately failed, the therapeutic potential of targeting other modifications remains to be seen. Recently, it was shown that acetylation of lysine 104 attenuates K-RAS transforming activity by interfering with GEF-induced nucleotide exchange. Here, the deacetylases HDAC6 and SIRT2 were shown to regulate the acetylation state of K-RAS in cancer cells. By extension, inhibition of either of these enzymes has a dramatic impact on the growth properties of cancer cells expressing activation mutants of K-RAS. These results suggest that therapeutic targeting of HDAC6 and/or SIRT2 may represent a new way to treat cancers expressing mutant forms of K-RAS. (C) 2013 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据